- Home
- NYC vs SCNX Comparison
NYC vs SCNX Comparison
Compare NYC & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NYC | SCNX |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Other Pharmaceuticals |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 16.2M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NYC | SCNX |
|---|---|---|
| Price | $5.66 | $3.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.4K | ★ 690.4K |
| Earning Date | 11-18-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,831,778.00 |
| Revenue This Year | $35.25 | $1,009.57 |
| Revenue Next Year | N/A | $259.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.72 |
| 52 Week Low | $5.52 | $0.18 |
| 52 Week High | $13.97 | $4.25 |
Technical Indicators
Market Signals| Indicator | NYC | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 32.67 | 92.31 |
| Support Level | N/A | $0.36 |
| Resistance Level | $8.89 | N/A |
| Average True Range (ATR) | 0.40 | 0.20 |
| MACD | 0.03 | 0.45 |
| Stochastic Oscillator | 10.53 | 93.39 |
Price Performance
Historical ComparisonAbout NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.